Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia

Kevin T McVary, Bradley Holland, J Randolf Beahrs, Kevin T McVary, Bradley Holland, J Randolf Beahrs

Abstract

Background: Water vapor thermal therapy utilizes convectively delivered thermal energy to target ablation of obstructive prostatic tissue. We report results of this thermal therapy for relief of nonneurogenic complete urinary retention associated with BPH.

Patients and methods: We conducted a retrospective analysis of 38 catheter-dependent men with complete urinary retention consecutively enrolled in a registry in two centers: median age 75.5 years and multiple comorbidities, median prostate volume 58.5 cc (23-153), median 2 failed trials without catheter (TWOCs), and median catheter dependency 3 months (0.3-35). The Rezūm™ System thermal therapy procedure was performed in an ambulatory surgery center with conscious sedation or an office procedure room with a modified periprostatic block. Water vapor injections were customized to the configuration of the hyperplastic gland, including median lobe and/or enlarged central zone.

Results: Of the 38 treated patients, one was lost to follow-up and 26 of 37 (70.3%) voided spontaneously (mean of 1.6 ± 0.8 TWOCs) and were catheter free a median of 26 days (range 4-65) after the procedure; 18 of these 26 (69%) patients discontinued BPH medications. No significant differences in age, prostate volume, number of water vapor injections, or presence of the median lobe were associated with predicting a successful treatment outcome. Duration of follow-up for 20 catheter-free patients was a median of 475 days or 15.8 months (140-804 days); six patients were followed a median of 31.5 days (0-60). Adverse events were infrequent, mild, and resolved quickly including dysuria in five patients (13%), gross hematuria in four (10.5%), and UTIs in two (2.6%) with indwelling catheters.

Conclusions: Water vapor thermal therapy may provide an effective and safe alternative to surgical treatment in this group of catheter-dependent patients in complete urinary retention.

Conflict of interest statement

KTM served as clinical study investigators on the pivotal trial of the water vapor thermal therapy (Rezūm System) sponsored by NxThera, Inc. (acquired by Boston Scientific) and has consulted for Boston Scientific and received compensation. JRB served as a clinical study investigator on the pivotal trial of water vapor thermal therapy sponsored by NxThera, Inc. BH declares no potential conflict of interest. The authors received no commercial funding or personal compensation for conduct of the Rezūm Registry Study.

References

    1. McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy (WAVE) ablation: a multicenter, randomized, controlled study for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195:1529–39. doi: 10.1016/j.juro.2015.10.181.
    1. Woo HH, Gonzalez RR. Perspective on the Rezūm System: a minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Dev. 2017;10:71–80.
    1. Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter post-market experience using minimally invasive convective radiofrequency thermal therapy with Rezūm System for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159–68.
    1. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019;126:171–9. doi: 10.1016/j.urology.2018.12.041.
    1. Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;200:612–9. doi: 10.1016/j.juro.2018.05.048.
    1. Gupta N, Rogers T, Holland B, Helo S, Dynda D, McVary KT, et al. Three-year treatment outcomes of water vapor thermal therapy (Rezūm System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. J Urol. 2018;200:405–13. doi: 10.1016/j.juro.2018.02.3088.
    1. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient’s perspective. Can J Urol. 1999;6:819–22.
    1. Brasure M, Fink HA, Risk M, MacDonald R, Shamliyan T, Ouellette J, et al. Chronic urinary retention: comparative effectiveness and harms of treatments. comparative effectiveness review no. 140. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2007-10064-I.) AHRQ publication no. 14-EHC041-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014. .
    1. Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR. The Rezūm system – a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia. Can J Urol. 2019;26:9787–93.
    1. Losco G, Mark S, Jowitt S. Transurethral prostate resection for urinary retention: does age affect outcome? ANZ J Surg. 2013;83:243–5. doi: 10.1111/ans.12014.
    1. Gujral S, Abrams P, Donovan JL, Neal DE, Brookes ST, Chacko KN, et al. A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: the CLasP study. J Urol. 2000;164:59–64. doi: 10.1016/S0022-5347(05)67449-6.
    1. Emberton M, Neal DE, Black N, Harrison M, Fordhams M, McBrien MP, et al. The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br J Urol. 1995;75:301–16. doi: 10.1111/j.1464-410X.1995.tb07341.x.
    1. Doll HA, Black A, McPherson K, Williams GB, Smith JC. Differences in outcome of transurethral resection of the prostate for benign prostatic hypertrophy between three diagnostic categories. Br J Urol. 1993;72:322–30. doi: 10.1111/j.1464-410X.1993.tb00727.x.
    1. Djavan B, Wammack R, Ghawidel K, Alavi S, Hasenzagel C, Dobronski P, et al. Microwave thermotherapy in patients with chronic urinary retention. Tech Urol. 2000;6:278–81.
    1. Naqvi SA, Rizvi SA, Hasan AS. High-energy microwave thermotherapy in patients in urinary retention. J Endourol. 2000;14:677–81. doi: 10.1089/end.2000.14.677.
    1. Schelin S. Microwave thermotherapy in patients with benign prostatic hyperplasia and chronic urinary retention. Eur Urol. 2001;39:400–4. doi: 10.1159/000052476.
    1. Kellner DS, Armenakas NA, Brodherson M, Heyman J, Fracchia JA. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia. Urology. 2004;64:703–6. doi: 10.1016/j.urology.2004.04.074.
    1. Schelin S, Geertsen U, Walter S, Spånberg A, Duelund-Jacobsen J, Krøyer K, et al. Feedback microwave thermotherapy versus TURP/prostate enucleation surgery in patients with benign prostatic hyperplasia and chronic urinary retention: a prospective, randomized, controlled, multicenter study. Urology. 2006;68:795–9. doi: 10.1016/j.urology.2006.05.020.
    1. Aagaard MF, Niebuhr MH, Jacobsen JD, Krøyer Nielsen K, et al. Transurethral microwave thermotherapy treatment of chronic urinary retention in patients unsuitable for surgery. Scand J Urol. 2014;48:290–4. doi: 10.3109/21681805.2013.840857.
    1. Wagrell L, Schelin S, Nordling J, Richtoff J, Magnusson B, Schain M, et al. Three-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology. 2004;64:699–702. doi: 10.1016/j.urology.2004.05.030.
    1. Stoffel JT, Peterson AC, Sandhu JS, Suskind AM, Wei JT, Lightner DJ. AUA white paper on nonneurogenic chronic urinary retention: Consensus definition, treatment algorithm, and outcome end points. J Urol. 2017;198:153–60. doi: 10.1016/j.juro.2017.01.075.
    1. D’Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38:433–77. doi: 10.1002/nau.23897.
    1. Negro CLA, Muir GH. Chronic urinary retention in men: how we define it, and how does it affect treatment outcome. BJU Int. 2012;110:1590–4. doi: 10.1111/j.1464-410X.2012.11101.x.
    1. Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD. Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol. 2008;180:47–54. doi: 10.1016/j.juro.2008.03.027.
    1. Helfand BT, Fought A, Manvar AM, McVary KT. Determining the utility of recalled lower urinary tract symptoms. Urology. 2010;76:442–7. doi: 10.1016/j.urology.2009.12.052.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere